Scalable expansion of human iNKT cells: single-cell profiling and in vivo control of GvHD with preserved GvL activity
Invariant natural killer T (iNKT) cells can limit graft-versus-host disease (GVHD) after hematopoietic stem cell transplantation (HSCT), but their scarcity in peripheral blood limits therapeutic development. Current clinical-grade human iNKT expansion protocols mainly rely on IL-2, require prior iNKT-cell sorting, last 6–8 weeks, and predominantly expand CD4+ iNKT cells, whereas human CD4− iNKT cells are more strongly associated with GVHD control in patients and uniquely regulate antigen-presenting cells and T-cell activation. We developed a scalable culture system to preferentially expand human CD4− iNKT cells directly from total peripheral blood mononuclear cells (PBMCs) using alpha-galactosylceramide (α-GalCer) and optimized cytokine conditions. IL-15 was the most effective cytokine. The optimized 14-day protocol generated a mean of 3.8×107 iNKT cells from 2×107 PBMCs, including 74% CD4− iNKT cells. Single-cell transcriptomic profiling identified eight major iNKT subsets, differentiation trajectories during expansion, and distinct IL-2- versus IL-15-associated transcriptional programs. IL-15-expanded iNKT cells induced apoptosis of monocyte-derived dendritic and leukemic cells in vitro, controlled xeno-GVHD, and preserved graft-versus-leukemia (GVL) activity in preclinical mouse models. This platform enables reproducible production of human CD4− iNKT cells at clinically relevant scale and position IL-15–expanded iNKT cells as a compelling immunotherapy candidate for allo-HSCT.